Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Urinary calculus

3

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

2

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Muscarinic acetylcholine receptor M1

2

Muscarinic acetylcholine receptor M2

2

Muscarinic acetylcholine receptor M3

2

Muscarinic acetylcholine receptor M4

2

Catechol O-methyltransferase

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1953

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

ECHA (EC/EINECS)

3

EPA CompTox

3

EVMPD

3

FDA UNII

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS

1

DRUGS FOR FUNCTIONAL BOWEL DISORDERS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Synthetic anticholinergic agents in combination with psycholeptics

1

Synthetic anticholinergics, quaternary ammonium compounds

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

PROPANTHELINE

1306V2B0Q8

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1953

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M4

Conditions:

Overactive bladder

Urinary calculus

Propantheline is an antimuscarinic agent used for the treatment of excessive sweating (hyperhidrosis), cramps or spasms of the stomach, intestines (gut) or bladder, and involuntary urination (enuresis). It can also be used to control the symptoms of ...

irritable bowel syndrome and similar conditions. Propantheline is one of a group of antispasmodic medications which work by blocking the action of the chemical messenger acetylcholine, which is produced by nerve cells, to muscarinic receptors present in various smooth muscular tissues, in places such as the gut, bladder, and eye. Normally, the binding of acetylcholine induces involuntary smooth muscular contractions. Varying degrees of drying of salivary secretions may occur as well as decreased sweating. Ophthalmic side effects include blurred vision, mydriasis, cycloplegia, and increased ocular tension. Other reported adverse reactions include urinary hesitancy and retention, tachycardia, palpitations, loss of the sense of taste, headache, nervousness, mental confusion, drowsiness, weakness, dizziness, insomnia, nausea, vomiting, constipation, bloated feeling, impotence, suppression of lactation, and allergic reactions or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.

FLOPROPIONE

05V5NVB5Y1

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Catechol O-methyltransferase

Conditions:

Biliary dyskinesia

Urinary calculus

Post-cholecystectomy syndrome

Flopropione is an antispasmodic agent developed to relieve spasms in patients with hepatobiliary disorders, pancreatitis and urinary calculus. The mode of action is based on the inhibition of catechol-o-methyl-transferase (COMT), resulting in an adre...

nergic action, and anti-serotonin action. The current marketing status of the drug is unknown and considered to be "discontinued".

PROPANTHELINE BROMIDE

UX9Z118X9F

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1953

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M4

Conditions:

Overactive bladder

Urinary calculus

Propantheline is an antimuscarinic agent used for the treatment of excessive sweating (hyperhidrosis), cramps or spasms of the stomach, intestines (gut) or bladder, and involuntary urination (enuresis). It can also be used to control the symptoms of ...

irritable bowel syndrome and similar conditions. Propantheline is one of a group of antispasmodic medications which work by blocking the action of the chemical messenger acetylcholine, which is produced by nerve cells, to muscarinic receptors present in various smooth muscular tissues, in places such as the gut, bladder, and eye. Normally, the binding of acetylcholine induces involuntary smooth muscular contractions. Varying degrees of drying of salivary secretions may occur as well as decreased sweating. Ophthalmic side effects include blurred vision, mydriasis, cycloplegia, and increased ocular tension. Other reported adverse reactions include urinary hesitancy and retention, tachycardia, palpitations, loss of the sense of taste, headache, nervousness, mental confusion, drowsiness, weakness, dizziness, insomnia, nausea, vomiting, constipation, bloated feeling, impotence, suppression of lactation, and allergic reactions or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1